首页> 外文期刊>Multidisciplinary Respiratory Medicine >The value of FeNO measurement in childhood asthma: uncertainties and perspectives
【24h】

The value of FeNO measurement in childhood asthma: uncertainties and perspectives

机译:FeNO测定在儿童哮喘中的价值:不确定性和前景

获取原文
       

摘要

Asthma is considered an heterogeneous disease, requiring multiple biomarkers for diagnosis and management. Fractional exhaled nitric oxide in exhaled breath (FeNO) was the first useful non-invasive marker of airway inflammation in asthma and still is the most widely used. The non-invasive nature and the relatively easy use of FeNO technique make it an interesting tool to monitor airway inflammation and rationalize corticosteroid therapy in asthmatic patients, together with the traditional clinical tools (history, physical examination and lung function tests), even if some controversies have been published regarding the use of FeNO to support the management of asthma in children. The problem of multiple confounding factors and overlap between healthy and asthmatic populations preclude the routine application of FeNO reference values in clinical practice and suggest that it would be better to consider an individual “best”, taking into account the context in which the measurement is obtained and the clinical history of the patient. Besides, there is still disagreement about the role of FeNO as a marker of asthma control, due to the complexity of balance among the different items involved in its determination and the lack of homogeneity in the population groups studied in the few studies conducted so far. Heterogeneity of problematic severe asthma greatly limits utility of FeNO alone as a biomarker of inflammation to optimize the disease management on an individual basis. None of the studies conducted so far demonstrated that the use of FeNO was better than current asthma guidelines in controlling asthma exacerbations. In summary, there is a large variation in FeNO levels between individuals, which may reflect the natural heterogeneity in baseline epithelial nitric oxide synthase activity and/or the contribution of other noneosinophilic factors to epithelial nitric oxide synthase activity. FeNO is a promising biomarker, but at present some limits are highlighted. We would recommend that further research can be carried out by organizing studies aimed to obtain reliable reference values of FeNO and in order to better interpret FeNO measurements in clinical settings, taking also into account the influence of genetic and environmental factors.
机译:哮喘被认为是一种异质性疾病,需要多种生物标记物进行诊断和管理。呼气中的呼出气一氧化氮(FeNO)是哮喘中气道炎症的第一个有用的非侵入性标记,并且仍是最广泛使用的标记。 FeNO技术的无创性和相对易用性使其成为监测哮喘患者气道炎症和合理使用皮质类固醇治疗的有趣工具,以及传统的临床工具(病史,体格检查和肺功能检查),即使有些关于使用FeNO来支持儿童哮喘控制的争议已经发表。多种混杂因素以及健康人群和哮喘人群之间的重叠问题排除了在临床实践中常规应用FeNO参考值的可能性,并建议考虑到获得测量的背景,考虑单个“最佳”更好以及患者的临床病史。此外,由于到目前为止,在进行的少数研究中,FeNO决定哮喘涉及的不同项目之间平衡的复杂性以及缺乏同质性的人群中,FeNO作为哮喘控制指标的作用仍然存在分歧。有问题的严重哮喘的异质性极大地限制了单独使用FeNO作为炎症的生物标志物来优化个体疾病管理的效用。迄今为止进行的任何研究均未证明在控制哮喘急性发作方面,FeNO的使用优于当前的哮喘指南。总之,个体之间的FeNO水平存在较大差异,这可能反映了基线上皮一氧化氮合酶活性的自然异质性和/或其他非嗜酸性因子对上皮一氧化氮合酶活性的贡献。 FeNO是一种有前途的生物标志物,但目前有一些限制。我们建议,可以通过组织旨在获得可靠的FeNO参考值的研究来进行进一步的研究,以便在考虑到遗传和环境因素的影响的情况下更好地解释临床环境中的FeNO测量值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号